Normal Dog Plasma Research Articles

Secretion and uptake of copper via a small copper carrier in blood fluid.

Studies with Wilson disease model mice that accumulate excessive copper, due to a dysfunctional ATP7B “copper pump” resulting in decreased biliary excretion, showed that the compensatory increase in urinary copper loss was due to a small copper carrier (∼1 kDa) (SCC). We show here that SCC is also present in the blood plasma of normal and Wilson disease model mice and dogs, as determined by ultrafiltration and size exclusion chromatography (SEC). It is secreted by cultured hepatic and enterocytic cells, as determined by pretreatment with 67Cu nitrilotriacetate (NTA) or nonradioactive 5–10 μM Cu-NTA, and collecting and examining 3 kDa ultrafiltrates of the conditioned media, where a single major copper peak is detected by SEC. Four different cultured cell types exposed to the radiolabeled SCC all took up the 67Cu at various rates. Rates differed somewhat when uptake was from Cu-NTA. Uptake of SCC-67Cu was inhibited by excess nonradioactive Cu(I) or Ag(I) ions, suggesting competition for uptake by copper transporter 1 (CTR1). Knockout of CTR1 in fibroblasts reduced uptake rates by 60%, confirming its participation, but also involvement of other transporters. Inhibitors of endocytosis, or an excess of metal ions taken up by divalent metal transporter 1, did not decrease SCC-67Cu uptake. The results imply that SCC may play a significant role in copper transport and homeostasis, transferring copper particularly from the liver (but also intestinal cells) to other cells within the mammalian organism, as well as spilling excess into the urine in copper overload—as an alternative means of copper excretion.

268. Enhanced Gene Expression of Factor VIII by Ultrasound-Mediated Gene Delivery in Dogs

Previously we demonstrated that ultrasound (US)-mediated gene delivery (UMGD) can significantly enhance reporter gene transfer into the mouse and rat livers. This nonviral gene transfer strategy can bypass many obstacles encountered by viral gene therapy. Most significantly, we have achieved therapeutic levels of FVIII following UMGD into hemophilia A mice. Recently we have successfully developed prototype US systems including several unfocused and semi-focused transducers to treat large tissue volumes in canine and swine. In order to facilitate the translation of this technology to treat hemophilia, we have recently treated 2 normal dogs with UMGD of FVIII plasmids using an open surgery procedure. Four mg of a high-expressing, liver-specific pBS-HCRHPI-FVIIIA plasmid and 3 ml of Definity® MBs in 8 ml total PBS solution were injected via the segmental portal vein branch with simultaneous exposure of the target liver lobe to therapeutic US (1.1 MHz frequency, 20 cycle pulses, 50 Hz pulse repetition frequency) for 4 minutes using the large diameter transducers. A sham-treated dog received an equivalent pGL4/MB dose, but was not exposed to tUS. We used an apodized dual element unfocused transducer H105 at 2.5Mpa peak negative pressure (PNP) in the first dog experiment and observed low levels of hFVIII gene expression in the treated liver lobes. The second dog experiment was performed using a cylindrically 6.2 MPa at the focal area. One day following treatment, the treated liver lobes were sectioned, and representative sections were fixed and stained for FVIII expression by histochemical staining using a polyclonal anti-FVIII antibody. Untreated normal dog liver and human liver were used as negative and positive controls. Significant hFVIII gene expression was obtained in both treated liver lobes with the expression levels slightly lower than control human liver lobe. Furthermore, fairly homogeneous distribution of FVIII gene expression was observed in hepatocytes. Next, we performed Western blot analysis to confirm if the staining is specific to human FVIII protein. A heavy chain band specific to hFVIII was observed in treated dog plasma and positive hFVIII control, but not in control normal dog plasma and pre-bleed plasma sample from the dog before treatment. Significant enhancement of FVIII-specific clotting activity was also obtained in the second treated dog compared to pre-treatment and the first treated dog. In addition, transaminase levels and histology analysis indicated minimal tissue damage in treated dog livers. Enhancement of FVIII gene expression by UMGD is currently evaluated in hemophilia dogs. Our results sugges that UMGD has great potential for therapeutic treatment of hemophilia A.

Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease

ObjectivesSerotonin has been implicated in canine myxomatous mitral valve disease (MMVD); however, the sources of serotonin have not been fully elucidated. This study compared the concentration of serotonin in plasma and platelets of normal healthy small breed dogs with predisposition to MMVD and dogs with naturally occurring MMVD. Animals43 small-breed client-owned dogs with an approximate weight of <10 kg and age of 6 years or above were divided into 2 groups: a healthy control group (n = 20) and a group with echocardiographic evidence of MMVD (n = 23). Methods5 ml samples of blood were collected. Plasma and platelets were separated by centrifugation and assayed for serotonin measured by enzyme linked immunosorbent assay (ELISA). ResultsMedian plasma serotonin concentration was not significantly different (p = 0.3630) between normal healthy dogs (3.7 ng/ml) and dogs with MMVD (4.3 ng/ml). Males had higher plasma serotonin concentration than females (4.7 and 2.9 ng/ml respectively, p = 0.0043). Platelet serotonin concentration was not different between healthy dogs and dogs with MMVD (128.6 ng/109 platelets and 176.6 ng/109 platelets respectively, p = 0.4575). Age, echocardiographic indices and platelet count showed no correlation with plasma or platelet serotonin concentration. ConclusionsCirculating plasma serotonin is unlikely a major source of serotonin signaling in canine MMVD. Platelets could be a source of serotonin in canine MMVD through platelet adhesion to the mitral valve; however, the amount of serotonin stored in platelets of healthy dogs and dogs with MMVD is not different.

Testicular Steroids, Prolactin, Relaxin and Prostate Gland Markers in Peripheral Blood and Seminal Plasma of Normal Dogs and Dogs with Prostatic Hyperplasia

Concentrations of 17β-oestradiol (E(2) ), testosterone (T), 5α-dihydrotestosterone, prolactin (PRL) and relaxin (RLN) were determined in peripheral blood serum or plasma and prostatic secretion of 77 physically healthy intact male dogs (19 Rhodesian Ridgebacks/RR, 58 dogs of other breeds, 1-9 years of age). Furthermore, the concentrations of acid phosphatase in prostatic secretion and canine prostate-specific esterase (CPSE) were measured in blood plasma. All dogs were submitted to a complete breeding soundness examination, including B-mode sonography. Prostatic volume was larger, and blood plasma levels of CPSE were higher in ageing dogs and in dogs with benign prostatic hyperplasia (BPH) compared with young dogs and dogs with normal prostate. Furthermore, a higher E(2) /T ratio was found in dogs with BPH. Despite missing significant differences in PRL concentrations, the slight increases in PRL concentrations in the prostatic secretion observed both with increasing age and in dogs with BPH and the observed correlations between concentrations of PRL and testicular steroids may possibly indicate a role of PRL in the pathogenesis of canine BPH. Serum RLN concentrations were at similar level in all dogs. Regarding breed differences, an appreciably larger prostatic volume and higher concentration of CPSE were verified in RR than in other pure-bred dogs, confirming our suspicion of a premature enlargement of the prostate gland, which may result from a genetic disposition for BPH in this breed.

Soluble parasite antigens from Babesia canis do not directly activate the kallikrein system in dogs infected with Babesia canis

Soluble parasite antigens (SPA) from Babesia canis have been shown to induce protective immunity when used as vaccine. In order to explain the immune mechanisms of vaccination, the precise role of SPA in the pathogenesis of canine babesiosis is under investigation. Earlier studies suggested that the plasma kallikrein system is central in the pathogenesis of babesiosis, malaria and trypanosomosis, and significant plasma kallikrein activation during acute B. bovis and P. knowlesi infections has been described. In the studies presented here dogs were experimentally infected with B. canis to investigate whether the plasma kallikrein system is activated during babesiosis infection. Results showed that prekallikrein levels decreased during episodes of peak parasitaemia. No effect was found on the kallikrein levels. In order to determine whether B. canis SPA could activate plasma kallikrein, dogs were infused with variable amounts of B. canis SPA and plasma samples were taken for (pre-) kallikrein determination. The results indicated that B. canis SPA did not affect plasma (pre-) kallikrein levels. In addition, the effect of B. canis SPA on (pre-) kallikrein levels in normal dog plasma was determined in vitro. Again, no effect on (pre-) kallikrein levels was found. The results suggest that, although the kallikrein pathway may be involved in B. canis-associated pathology, the system is not directly activated by B. canis SPA. Furthermore, infusion of B. canis SPA as well as stroma of normal dog erythrocytes triggered the production of the acute phase reactant, C-reactive protein. This suggests that the inflammatory response that is triggered during B. canis infection could be in part due to the release and exposure of self molecules. The implications of these findings are discussed.

Determination of canine beta2-microgloblin in plasma and urine by enzyme-linked immunosorbent assay.

An enzyme-linked immunosorbent assay was developed for the determination of canine beta2-microglobulin (beta2-m) in plasma and urine. The detectable sensitivity for pure canine beta2-m was 0.05 microg/l and the analytical range was 0.1 to 50 microg/l. The mean analytical recovery when pure canine beta2-m was added to normal plasma was 101.9%. The mean analytical recovery in the urine was 102.1%. The intra-day variation coefficient was 3.1% in plasma, 4.3% in serum and 1.9% in urine. No difference was found between the concentration of beta2-m in plasma and serum (n=17). The concentration of beta2-m in the plasma of normal dogs was 1.82 +/- 0.57 mg/l (n=31). The mean excretion in 24 hr urine collected from normal dogs was 17.6 +/- 9.2 microg/l, 0.22 +/- 0.12 microg/kg of body weight or 14.2 +/- 9.4 microg/g of urine creatinine. The beta2-m creatinine index of random urine samples was 23.5 +/- 16.6 microg/g (n=26). There was a close correlation between the beta2-m creatinine index of 24 hr urine samples and that of random urine samples (r=0.872).

Isolation and Characterization of Canine Factor IX

Canine plasma factor IX was purified to homogeneity by a combination of barium citrate precipitation and three-step column chromatographies of DEAE sepharose, heparin agarose and a monoclonal antifactor IX antibody-linked agarose. Canine factor IX has an apparent molecular size of 61 kDa, which is slightly smaller than that of human factor IX, as determined by denatured polyacrylamide gel electrophoresis. Its amino acid composition, amino-terminal and carboxyterminal amino acid sequences agreed well with those predicted from the reported cDNA. Unlike purified human factor IX, canine factor IX preparation often showed a discrete smaller molecular species (approximately 50 kDa) which was generated by a specific proteolytic cleavage between Arg310 and Val311. When purified canine factor IX was utilized as a standard for enzyme linked immunosorbent assay, the concentration of canine factor IX in the pooled normal dog plasma was determined to be 5.3 micrograms/ml with 11.2% carbohydrate content (or 4.7 micrograms/ml for its polypeptide chain moiety). Concentration of plasma factor IX antigen was measured in six severely affected, unrelated hemophilia B dogs. Four had factor IX antigen of less than 1% of the normal, and two had undetectable levels. The latter two had gross molecular abnormalities in their factor IX genes. Three obligate carrier females had variable but proportionately reduced factor IX antigen and factor IX coagulant activity levels. These results provide a quantitative method for measuring canine factor IX antigen which is a prerequisite for studying hemostasis and development of gene transfer approaches in the canine model of hemophilia B.

Grass pollen specific antibody in the plasma of normal dogs.

An investigation carried out with healthy beagle dogs showed that their plasmas contained detectable levels of grass pollen specific IgG antibody, as measured by a radiometric assay involving the binding of IgG to radio-iodinated staphylococcal protein A. These samples did not, however, contain detectable homocytotropic-type antibodies specific for grass pollen extract.

Absence of detectable immunoreactive alpha melanocyte stimulating hormone in plasma in various types of Cushing's disease.

We have measured alpha-MSH in plasma of normal subjects and subjects with various diseases of the pituitary-adrenocortical system using a radioimmunoassay with a sensitivity of 1.2 pmol/l. No alpha-MSH could be detected in plasma of normal subjects (n = 6), in plasma of patients with Addison's disease (n = 3), Nelson's syndrome (n = 2), bromocriptine responsive (n = 2) and unresponsive (n = 5) Cushing's disease and in plasma of psychiatric patients on chronic treatment with the dopamine antagonist haloperidol (n = 5). Plasma alpha-MSH remained undetectable in 2 patients with Cushing's disease after iv injection of 60 micrograms/kg haloperidol. In contrast, alpha-MSH was detectable in plasma of normal dogs (n = 2) and dogs with pituitary dependent hyperadrenocorticism (n = 2), whereas the iv injection of halo peridol was associated with a rise of plasma alpha-MSH. Thus we are unable to detect circulating alpha-MSH in man despite the use of a sensitive radioimmunoassay.

Release of Dog Polymorphonuclear Leukocyte Cathepsin G, Normally and in Endotoxin and Pancreatitic Shock. Isolation and Partial Characterization of Dog Polymorphonuclear Leukocyte Cathepsin G

Dog polymorphonuclear leukocyte cathepsin G was isolated from a granule extract using a two-step procedure including affinity chromatography on a Trasylol-Sepharose gel and ion-exchange chromatography on a CM 52 column. 22 of the first 24 N-terminal amino acids were determined and showed 83% and 71% identity to those of human and rat cathepsin G, respectively. Total amino-acid composition demonstrated the basic nature of the protein. In an SDS/polyacrylamide-gel electrophoresis the protein showed an Mr of 29,400 compared to the Mr of 26,800 calculated from the total amino-acid composition. The enzyme was shown to form complexes with alpha 1 alpha 2-macroglobulin and alpha 1-proteinase inhibitor. A specific enzyme-linked immunosorbent assay was developed for the determination of cathepsin G/alpha 1-proteinase inhibitor complex in dog plasma and tissue fluids. The mean concentration of cathepsin G in normal dog plasma was determined to be 38 micrograms/l, measured as cathepsin G/alpha 1-proteinase inhibitor complex. When active dog cathepsin G was added to normal dog plasma in vitro, approximately 56% could be measured by the assay. Slow intravenous infusion of a lethal dose of endotoxin in dogs was followed by a marked drop in white blood cell count and thrombocytes and a simultaneous rapid increase in plasma cathepsin G concentration, reaching a maximum level of 150 micrograms/l. Bile-induced experimental pancreatitis in dogs was accompanied by successive increase in cathepsin G levels in plasma as well as in peritoneal exudates, reaching a maximum level of about 300 micrograms/l in plasma and 18 mg/l in the exudates during the late stages of disease.

Metabolism of canine beta-very low density lipoproteins in normal and cholesterol-fed dogs.

Cholesteryl ester-rich beta-very low density lipoproteins (beta-VLDL) are beta-migrating lipoproteins that accumulate in the plasma of cholesterol-fed animals and of patients with type III hyperlipoproteinemia. There are two distinct fractions: fraction I beta-VLDL are chylomicron remnants of intestinal origin, and fraction II beta-VLDL are cholesterol-rich VLDL of hepatic origin. The liver rapidly clears fraction I beta-VLDL from the plasma of both normal and cholesterol-fed dogs. The liver also clears fraction II beta-VLDL rapidly and efficiently from the plasma of normal dogs by receptor-mediated uptake. In cholesterol-fed dogs the clearance is biphasic: an initial rapid die-away of about 30% to 40% of the injected dose within 5 minutes, followed by a slow clearance of plasma radioactivity (a half-life of more than 20 hours). The rapid, initial phase of fraction II beta-VLDL clearance appears to be related to sequestration of the lipoproteins presumably on endothelial cells and is apparently associated with lipolytic processing. Treatment of the fraction II beta-VLDL with lipoprotein lipase abolishes this rapid phase. In the cholesterol-fed dog, the slow, late phase of clearance corresponds to the conversion of fraction II beta-VLDL to the smaller, denser intermediate and low density lipoproteins (IDL and LDL), which are slowly cleared from the plasma. It is concluded that fraction II beta-VLDL are catabolized in the normal dog by rapid uptake mediated at least in part by the apo B,E(LDL) receptor of hepatic parenchymal cells. In cholesterol-fed dogs, in which these receptors are markedly down-regulated, fraction II beta-VLDL are apparently initially bound to endothelial cells and converted to IDL and LDL by lipolytic processing.

In Vivo Effects of a Low Molecular Weight Heparin Fragment on Platelet Aggregation and Platelet Dependent Hemostasis in Dogs

Plasma defibrinogenated dogs were used to study the influence of conventional heparin and a low molecular weight heparin fragment (Fragmin, mean MW 5,000 d) on platelet dependent hemostasis. The heparins were given intravenously in gravimetrically equal doses. The bleeding from standardized skin flap wounds and platelet aggregation (ADP and thrombin) was studied. In comparison, higher doses of the fragment than of heparin were required to increase the bleeding. ADP-induced aggregation in defibrinogenated platelet rich plasma (after addition of normal dog plasma) was potentiated by both heparins. After injection of heparin or the fragment, ADP induced platelet aggregation without prior addition of normal plasma to the test-tube. In conclusion the heparin fragment affected bleeding to a less extent than conventional heparin. One explanation might be a weaker inhibition of thrombin-induced platelet aggregation.

Analysis and distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in biological specimens.

We have developed a sensitive (100 ppb), easily performed high performance liquid chromatography (ultraviolet) assay for 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in biological fluids and tissues. This assay has been used to determine drug levels in plasma and brain of normal dogs receiving BCNU (10 mg/kg) with three infusion protocols: (a) intravenous (5- to 10-minute infusion), (b) intracarotid (30- to 60-minute infusion), and (c) intracarotid (10-minute infusion). The levels of BCNU in the ipsilateral brain were maximized (11.0 and 14.4 micrograms/ml) after the 10-minute intracarotid administration. These levels were 2- to 3-fold greater than those seen using alternative infusions. These direct measurement studies provide strong support for intracarotid BCNU therapy of patients with malignant glioma,

Pancreatitis-associated ascitic fluid: effect on the oxygen consumption of liver cells.

AbstractWe examined the effect of pancreatitis-associated ascitic fluid (PAAF) on the oxidative activity of rat liver cells and found a depression with eight of nine dog PAAF samples. Pancreatitis was induced in dogs by retrograde pancreatic duct infusion of bile salts plus trypsin. The resultant PAAF was collected, passed through a sterile 0.22–μm Micropore filter to remove bacteria and other debris, and stored at −18° until used. Liver cells were obtained from minced Sprague—Dawley rat livers by gentle homogenization and filtration through a nylon mesh filter to produce a cell suspension. The oxygen utilization of liver cells incubated at 37° with a 1:50 dilution of PAAF was compared to controls incubated with normal dog plasma. The oxygen uptake of PAAF-treated cells was significantly lower with seven of nine ascitic fluids and the depression in oxygen consumption was found to be dose dependent over the range of 10 to 80 μl PAAF. One human PAAF sample was tested and it caused a 72% decrease in liver ce...

Chylomicron metabolism during dietary-induced hypercholesterolemia in dogs.

The metabolism of [1-3H]retinol- and [4-14C]cholesterol-labeled chylomicrons was studied in normal and cholesterol-fed dogs in order to estimate the relative contribution of chylomicron remnant cholesterol to diet-induced hypercholesterolemia. The plasma t 1/2 of intravenously administered Sf greater than 400 chylomicrons, Sf 20-400 chylomicrons, and whole lymph doubly labeled with [1-3H]retinol and [4-14C]cholesterol was not significantly prolonged in hypercholesterolemic recipients. When Sf greater than 400 chylomicrons were administered intravenously, 90% of the radioactivity was cleared from the plasma of both normal and cholesterol-fed dogs within 1 hr and 68 +/- 18% appeared in the liver within approximately 2 hr in normal dogs and 4 hr in hypercholesterolemic dogs. The use of the retinol-labeling technique for intestinal lipoproteins provided evidence that some LDL, but essentially none of the HDLc, was derived from d greater than 1.006 g/ml lymph lipoproteins. The failure of significant radioactivity to accumulate in the plasma compartment of hypercholesterolemic dogs after intravenous administration of doubly labeled chylomicrons and the relatively efficient uptake of radioactivity by the liver indicate that the dietary-induced hypercholesterolemia in dogs is not the result of impaired hepatic removal of chylomicron remnants.

Detection of serum cardiac myosin light chains in acute experimental myocardial infarction: radioimmunoassay of cardiac myosin light chains

To develop a more specific plasma test for myocardial infarction, antibodies specific for cardiac myosin light chains (CM-LC) were elicited that showed less than 3% cross-reactivity with skeletal muscle light chains. These antibodies were used to develop a radioimmunoassay for CM-LC that had a sensitivity of 20 ng (+/- 4 SD; P less than 0.001). Normal dog plasma showed no measurable concentrations of CM-LC (n = 6). Plasma samples from 10 dogs with experimental myocardial infarction produced by persistent left anterior descending coronary artery (LAD) occlusion were obtained at 0, 2, 4, 6, 24, 48 and 72 hours. CM-LC were first detectable in all 10 animals 6 hours after occlusion (97.98 +/- 14 ng/ml [mean +/- SEM]; P less than 0.001). Maximal CM-LC levels were usually obtained between 24 and 48 hours. Sham-operated open chest dogs (0--48 hours, n = 3) showed no measurable CM-LC in the plasma samples. Another group of 10 dogs were subjected to 5 hours of LAD occlusion, followed by reperfusion. In four dogs, ...

Detection of serum cardiac myosin light chains in acute experimental myocardial infarction: radioimmunoassay of cardiac myosin light chains.

To develop a more specific plasma test for myocardial infarction, antibodies specific for cardiac myosin light chains (CM-LC) were elicited that showed less than 3% cross-reactivity with skeletal muscle light chains. These antibodies were used to develop a radioimmunoassay for CM-LC that had a sensitivity of 20 ng (+/- 4 SD; P less than 0.001). Normal dog plasma showed no measurable concentrations of CM-LC (n = 6). Plasma samples from 10 dogs with experimental myocardial infarction produced by persistent left anterior descending coronary artery (LAD) occlusion were obtained at 0, 2, 4, 6, 24, 48 and 72 hours. CM-LC were first detectable in all 10 animals 6 hours after occlusion (97.98 +/- 14 ng/ml [mean +/- SEM]; P less than 0.001). Maximal CM-LC levels were usually obtained between 24 and 48 hours. Sham-operated open chest dogs (0--48 hours, n = 3) showed no measurable CM-LC in the plasma samples. Another group of 10 dogs were subjected to 5 hours of LAD occlusion, followed by reperfusion. In four dogs, CM-LC were detectable as early as 1 hour after reperfusion (81.88 +/- 37.75 ng/ml serum). Sera from all 10 dogs showed elevated levels of CM-LC (199.75 +/- 24.0 ng/ml) by 24 hours. Peak CM-LC concentrations were obtained in five dogs at 24 hours (247.0 +/- 35.28 ng/ml) and in another dog at 120 hours (245 ng/ml). Histochemical infarct size was determined to be 0.5--10% of the left ventricular mass at seven days by triphenyltetrazolium chloride staining. The specificity and sensitivity of this radioimmunoassay for detection of CM-LC, unique proteins to the heart, may be valuable in the diagnosis of myocardial infarction.

Effect of hemoperfusion of clearance of gentamicin, cephalothin, and clindamycon from plasma of normal dogs.

Nine normal dogs were divided into three groups of three. Group 1 was given an overdose of gentamicin; group 2, cephalothin; and group 3, clindamycin. Group 1 had hemoperfusion with Amberlite XE-336, and groups 2 and 3 with Amberlite XAD-4 resin adsorbents, for 6 hr with a blood flow rate of 300 ml/min. The plasma clearance and removal rates of antibiotics by the hemoperfusion columns were high. The clearance rate of gentamicin from plasma (mean +/- standard deviation) ranged from 59 +/- 30 to 199 +/- 6 ml/min, of cephalothin from 66 +/- 14 to 157 +/- 8 ml/min, and of clindamycin from 55 +/- 9 to 125 +/- 16 ml/min. Of the total dose of antibiotic administered, the hemoperfusion columns removed 67% from theplasma in group 1, 41% in group 2, and 18% in group 3. The fact that antibiotics may be rapidly removed from the blood during hemoperfusion should be considered in calculation of the therapeutic dose of antibiotic required for patients who receive this preocedure. Also, hemoperfusion can effectively and rapidly remove certain antibiotics from the blood of patients who have had a potentially toxic overdose.

Immunoreactive somatostatin levels in plasma of normal and alloxan diabetic dogs

Immunoreactive somatostatin levels in plasma of normal and alloxan diabetic dogs

Depression of atrial contractility by peptides isolated from normal and shock plasma.

SummaryThe presence of peptides in normal dog plasma and in plasma of dogs subjected to hemorrhagic shock has been investigated. The column chromatographic elution pattern for both normal and hemorrhagic plasma samples were similar. Of the six peptide peaks in the column elution pattern, only one (peak III) produced significant depression of atrial contractile strength. The depression produced by the shock peak III sample was not significantly greater than the contractile depression produced by control peak III. The results indicate that the atrial contractile depression produced by this peptide could only be significant during circulatory shock if it in some way interacted with other abnormal conditions existing during the shock state.